Agile Therapeutics, Inc. affirmed revenue guidance for the year 2023. The company believe this affirms its confidence in its business plan, the company progress towards the goal of achieving 2023 net revenue in the range of $25 million to $30 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4297 USD | +7.42% | +9.06% | -77.96% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-77.96% | 2.74M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023